- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Patent holdings for IPC class C07D 261/18
Total number of patents in this class: 323
10-year publication summary
|
26
|
36
|
33
|
20
|
28
|
28
|
21
|
11
|
21
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 462 |
48 |
| Proteostasis Therapeutics, Inc. | 70 |
9 |
| F. Hoffmann-La Roche AG | 7920 |
8 |
| Sumitomo Chemical Company, Limited | 9002 |
7 |
| The Board of Trustees of the University of Illinois | 2682 |
7 |
| Denali Therapeutics Inc. | 238 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 163 |
7 |
| The University of Queensland | 657 |
7 |
| Bristol-myers Squibb Company | 4897 |
6 |
| Boehringer Ingelheim International GmbH | 4701 |
6 |
| Shionogi & Co., Ltd. | 868 |
6 |
| VALO Health, Inc. | 171 |
6 |
| Hoffmann-La Roche Inc. | 3369 |
5 |
| Cornell University | 3274 |
5 |
| Astellas Pharma Inc. | 1085 |
4 |
| Epizyme, Inc. | 370 |
4 |
| Theravance, Inc. | 68 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2837 |
4 |
| Vanderbilt University | 1886 |
4 |
| BASF SE | 20758 |
3 |
| Other owners | 166 |